Fresh analysis reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional diet and exercise regimens.
Findings released in a leading health publication points out that while overweight individuals can lose about a fifth of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these medications need to be informed of the danger of quick weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a return to starting weight in about 18 months.
Analyzing Approaches
The analysis, which reviewed dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through lifestyle changes alone usually see a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Experts believe the mechanism of the drugs accounts for the heightened weight return.
These medications mimic a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal might result in the system to produce less of its endogenous hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
The NHS recommend the injections for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who state that the results "underscore the long-term character of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
Individuals who have stopped the medication describe a sudden resurgence of hunger.
"It was like something that goes on and you become ravenous," said an individual.
The struggle is worsened if users have not developed sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Recent estimates show that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural changes.
